12.18
Schlusskurs vom Vortag:
$12.05
Offen:
$11.95
24-Stunden-Volumen:
34,102
Relative Volume:
0.46
Marktkapitalisierung:
$316.12M
Einnahmen:
$26.00M
Nettoeinkommen (Verlust:
$-219.71M
KGV:
-0.2446
EPS:
-49.8
Netto-Cashflow:
$-51.37M
1W Leistung:
-10.31%
1M Leistung:
+24.80%
6M Leistung:
-36.10%
1J Leistung:
-27.72%
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Firmenname
Cartesian Therapeutics Inc
Sektor
Branche
Telefon
301-348-8698
Adresse
7495 NEW HORIZON WAY, FREDERICK
Vergleichen Sie RNAC mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RNAC
Cartesian Therapeutics Inc
|
12.18 | 352.46M | 26.00M | -219.71M | -51.37M | -49.80 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-09 | Eingeleitet | Wedbush | Outperform |
2024-12-19 | Eingeleitet | BTIG Research | Buy |
2024-08-06 | Eingeleitet | TD Cowen | Buy |
2024-07-02 | Herabstufung | Oppenheimer | Outperform → Perform |
2024-06-04 | Eingeleitet | Oppenheimer | Outperform |
2024-05-24 | Eingeleitet | Mizuho | Buy |
2024-04-23 | Bestätigt | H.C. Wainwright | Buy |
2024-04-23 | Eingeleitet | Leerink Partners | Outperform |
2023-08-18 | Herabstufung | SVB Securities | Outperform → Market Perform |
2022-06-14 | Bestätigt | Needham | Buy |
2022-06-06 | Eingeleitet | SVB Leerink | Outperform |
2021-06-15 | Eingeleitet | BTIG Research | Buy |
2021-01-26 | Hochstufung | Mizuho | Neutral → Buy |
2020-10-01 | Herabstufung | Mizuho | Buy → Neutral |
2020-10-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
2020-06-12 | Herabstufung | Stifel | Buy → Hold |
2020-04-28 | Eingeleitet | H.C. Wainwright | Buy |
2020-01-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-01-21 | Eingeleitet | William Blair | Outperform |
2018-06-27 | Eingeleitet | Janney | Buy |
2017-03-30 | Bestätigt | UBS | Buy |
Alle ansehen
Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten
Cartesian Therapeutics Inc. Stock Analysis and ForecastBreakout profit opportunities - Autocar Professional
Is Cartesian Therapeutics Inc. a good long term investmentStrongest growth potential - Autocar Professional
What drives Cartesian Therapeutics Inc. stock priceRapid growth trajectories - jammulinksnews.com
What analysts say about Cartesian Therapeutics Inc. stockFree Stock Market Forecast Reports - jammulinksnews.com
What makes Cartesian Therapeutics Inc. stock price move sharplyFree Stock Market Swing Trading Strategies - Newser
Multiple Myeloma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics - MenaFN
Why Cartesian Therapeutics Inc. stock attracts strong analyst attentionCarefully Curated High Return Stocks - Newser
How Cartesian Therapeutics Inc. stock performs during market volatilityShort Squeeze Radar - Newser
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $40.00 Average Price Target from Analysts - Defense World
What is Wedbush’s Estimate for RNAC Q2 Earnings? - Defense World
Cartesian Therapeutics Advances mRNA CAR T-cell Therapy for Myasthenia Gravis - TipRanks
Wedbush Initiates Coverage on Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
CartesianAutoimmune Cell Therapy Excites, But Reality Bites (NASDAQ:RNAC) - Seeking Alpha
Wedbush initiates coverage on Cartesian Therapeutics stock with Outperform rating - Investing.com Canada
Cartesian stock up as Wedbush becomes bullish (RNAC:NASDAQ) - Seeking Alpha
Cartesian Therapeutics' 15min chart sees KDJ Golden Cross, bullish Marubozu formation. - AInvest
Cartesian Therapeutics, Inc.(NasdaqGM: RNAC) added to Russell 3000 Value Index - MarketScreener
What caused RNAC's earnings to miss forecasts in Q4 2023? - AInvest
Rhumbline Advisers Grows Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
We're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate - Yahoo Finance
Myasthenia Gravis Market to Expand Significantly by 2034, States DelveInsight Report | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - The Globe and Mail
IBM Introduces Industry-First Software to Unify Agentic Governance and Security - The Globe and Mail
Cartesian Therapeutics holds annual stockholders meeting By Investing.com - Investing.com South Africa
Cartesian Therapeutics holds annual stockholders meeting - Investing.com
Cartesian Therapeutics Holds Annual Stockholders Meeting - TipRanks
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Acquired by Bank of America Corp DE - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Two Sigma Investments LP Reduces Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Equities Analysts Offer Predictions for RNAC FY2026 Earnings - Defense World
Nuveen Asset Management LLC Buys 47,889 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Cartesian Therapeutics Announces New Employment Inducement Grants | RNAC Stock News - GuruFocus
Cartesian Therapeutics (RNAC) Issues Inducement Stock Options to New Employees | RNAC Stock News - GuruFocus
Cartesian Therapeutics Awards 26,350 Stock Options to Key New Hires in Autoimmune Disease Research - Stock Titan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
H.C. Wainwright maintains buy rating on Cartesian Therapeutics stock By Investing.com - Investing.com Nigeria
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis - mx.advfn.com
Finanzdaten der Cartesian Therapeutics Inc-Aktie (RNAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cartesian Therapeutics Inc-Aktie (RNAC) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
English Emily | Chief Operations Officer |
Apr 15 '25 |
Option Exercise |
3.30 |
7,500 |
24,750 |
47,726 |
SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
48,595 |
508,751 |
620,175 |
SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
41,782 |
393,947 |
571,580 |
SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
36,338 |
391,455 |
656,513 |
SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
8,575 |
89,773 |
8,637,273 |
SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
7,373 |
69,517 |
8,628,698 |
SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
6,412 |
69,074 |
8,643,685 |
SPRINGER TIMOTHY A | Director |
Mar 20 '25 |
Buy |
15.59 |
54,889 |
855,593 |
8,621,325 |
SPRINGER TIMOTHY A | Director |
Mar 19 '25 |
Buy |
14.97 |
20,234 |
302,962 |
8,566,436 |
SPRINGER TIMOTHY A | Director |
Mar 18 '25 |
Buy |
14.42 |
14,740 |
212,599 |
8,546,202 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):